tradingkey.logo

Novartis AG

NVS

105.850USD

-6.400-5.70%
收盤 04/04, 16:00美東報價延遲15分鐘
209.06B總市值
17.51本益比TTM

Novartis AG

105.850

-6.400-5.70%
關於 Novartis AG 公司
諾華公司是一家總部位於瑞士的製藥公司。該公司開發、生產和銷售品牌和仿製藥處方藥、活性藥物成分 (API)、生物仿製藥和眼科產品。該公司利用科學和數字技術治療免疫學、皮膚病學、癌症、眼科、神經科學、呼吸、心血管、腎臟和代謝等疾病領域。該公司的業務活動分爲兩個部門:創新藥物部門,包括用於治療血壓、癌症和其他疾病的創新專利保護處方藥;山德士部門,包括仿製藥和生物仿製藥。
公司簡介
公司代碼NVS
公司名稱Novartis AG
上市日期May 07, 2001
成立日期1996
CEODr. Vasant (Vas) Narasimhan, M.D.
員工數量75883
證券類型Ordinary Share
年結日May 07
公司地址Lichtstrasse 35
城市BASEL
上市交易所Johannesburg Stock Exchange
國家Switzerland
郵編4056
電話41613241111
網址https://www.novartis.com/
公司代碼NVS
上市日期May 07, 2001
成立日期1996
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
Mr. Giovanni Caforio
Mr. Giovanni Caforio
Chairman of the Board
Chairman of the Board
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
Dr. Fiona H. Marshall, Ph.D.
Dr. Fiona H. Marshall, Ph.D.
President - Biomedical Research, Member of the Executive Committee
President - Biomedical Research, Member of the Executive Committee
--
--
Dr. Shreeram Aradhye, M.D.
Dr. Shreeram Aradhye, M.D.
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
President - Global Drug Development and Chief Medical Officer, Member of the Executive Committee
--
--
Dr. Simon E. Moroney
Dr. Simon E. Moroney
Independent Non-Executive Vice Chairman of the Board
Independent Non-Executive Vice Chairman of the Board
--
--
Ms. Karen L. Hale
Ms. Karen L. Hale
Chief Legal Officer, Member of the Executive Committee
Chief Legal Officer, Member of the Executive Committee
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Patrick Horber, M.D.
Mr. Patrick Horber, M.D.
President - International, Member of the Executive Committee
President - International, Member of the Executive Committee
--
--
Ms. Ana de Pro Gonzalo
Ms. Ana de Pro Gonzalo
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Elizabeth Mcnally
Ms. Elizabeth Mcnally
Director
Director
--
--
Mr. Giovanni Caforio
Mr. Giovanni Caforio
Chairman of the Board
Chairman of the Board
--
--
Mr. John D. Young
Mr. John D. Young
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Robert (Rob) Kowalski
Dr. Robert (Rob) Kowalski
Chief People and Organization Officer, Member of the Executive Committee
Chief People and Organization Officer, Member of the Executive Committee
--
--
收入明細
單位: USD更新時間: 4 小時前
單位: USD更新時間: 4 小時前
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
地區USD
名稱
營收
佔比
United States
21.15B
42.03%
Other Foreign-
18.51B
36.79%
China
3.89B
7.73%
Germany
3.66B
7.27%
France
1.79B
3.56%
Switzerland
1.31B
2.61%
業務
地區
業務USD
名稱
營收
佔比
Rest of portfolio
10.07B
20.02%
Cardiovascular, Renal and Metabolism - Entresto
7.82B
15.55%
Immunology - Cosentyx
6.14B
12.20%
Neuroscience - Kesimpta
3.22B
6.41%
Oncology -Kisqali
3.03B
6.03%
Other
20.02B
39.80%
股東統計
更新時間: 3月28日 週五
更新時間: 3月28日 週五
持股股東
股東類型
持股股東
股東統計
佔比
Dodge & Cox
0.62%
PRIMECAP Management Company
0.56%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.22%
Other
97.91%
持股股東
股東統計
佔比
Dodge & Cox
0.62%
PRIMECAP Management Company
0.56%
Dimensional Fund Advisors, L.P.
0.41%
Loomis, Sayles & Company, L.P.
0.28%
Franklin Mutual Advisers, LLC
0.22%
Other
97.91%
股東類型
股東統計
佔比
Investment Advisor
3.26%
Investment Advisor/Hedge Fund
2.64%
Research Firm
0.37%
Hedge Fund
0.28%
Bank and Trust
0.12%
Pension Fund
0.03%
Family Office
0.01%
Other
93.29%
機構持股
更新時間: 2月20日 週四
更新時間: 2月20日 週四
報告期間
機構數
持股數
持股佔比
持股變動
2025Q1
1884
133.48M
6.75%
-9.09M
2024Q4
1926
134.00M
6.78%
-9.24M
2024Q3
1858
134.89M
6.74%
-11.71M
2024Q2
1840
139.20M
6.87%
-9.16M
2024Q1
1808
141.30M
6.92%
-7.93M
2023Q4
1811
141.99M
6.94%
-15.97M
2023Q3
1775
150.92M
7.33%
-7.18M
2023Q2
1759
150.74M
7.28%
-24.15M
2023Q1
1762
167.49M
7.98%
-13.01M
2022Q4
1782
173.67M
8.19%
-17.15M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Dodge & Cox
12.21M
0.62%
-7.21K
-0.06%
Dec 31, 2024
PRIMECAP Management Company
11.03M
0.56%
-983.02K
-8.19%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
8.18M
0.41%
+90.82K
+1.12%
Dec 31, 2024
Loomis, Sayles & Company, L.P.
5.58M
0.28%
-192.68K
-3.34%
Dec 31, 2024
Franklin Mutual Advisers, LLC
4.26M
0.22%
-16.98K
-0.40%
Dec 31, 2024
Wellington Management Company, LLP
3.65M
0.18%
-351.31K
-8.78%
Dec 31, 2024
Morgan Stanley Smith Barney LLC
3.59M
0.18%
-52.88K
-1.45%
Dec 31, 2024
Parametric Portfolio Associates LLC
2.98M
0.15%
-86.17K
-2.81%
Dec 31, 2024
Managed Account Advisors LLC
2.95M
0.15%
-214.17K
-6.76%
Dec 31, 2024
Renaissance Technologies LLC
2.67M
0.14%
+368.17K
+16.00%
Dec 31, 2024
查看更多
持股ETF
更新時間: 17 小時前
更新時間: 17 小時前
機構名稱
佔比
VanEck Pharmaceutical ETF
5.37%
Cullen Enhanced Equity Income ETF
4.16%
Invesco International Dividend Achievers ETF
2.69%
Amplify International Enhanced Dividend Income ETF
2.67%
Altrius Global Dividend ETF
2.35%
SGI Enhanced Global Income ETF
2.07%
Pacer Global Cash Cows Dividend ETF
2.06%
Abacus FCF International Leaders ETF
1.9%
SP Funds S&P World (ex-US) ETF
1.78%
The Opal International Dividend Income ETF
1.74%
查看更多
VanEck Pharmaceutical ETF
佔比5.37%
Cullen Enhanced Equity Income ETF
佔比4.16%
Invesco International Dividend Achievers ETF
佔比2.69%
Amplify International Enhanced Dividend Income ETF
佔比2.67%
Altrius Global Dividend ETF
佔比2.35%
SGI Enhanced Global Income ETF
佔比2.07%
Pacer Global Cash Cows Dividend ETF
佔比2.06%
Abacus FCF International Leaders ETF
佔比1.9%
SP Funds S&P World (ex-US) ETF
佔比1.78%
The Opal International Dividend Income ETF
佔比1.74%
分紅派息
近5年累計派現 36.74B 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
Feb 20, 2025
NVS.NB Approximate final Cash Dividend of gross USD 3.869541 going ex on Mar 12, 2025
Mar 12, 2025
May 01, 2025
Mar 12, 2025
Feb 12, 2024
NVS.NB Final Cash Dividend of gross USD 3.739544 paid on Apr 19, 2024 going ex on Mar 07, 2024
Mar 08, 2024
Apr 19, 2024
Mar 07, 2024
Feb 02, 2023
NVS.NB Final Cash Dividend of gross USD 3.498699 paid on Mar 20, 2023 going ex on Mar 09, 2023
Mar 10, 2023
Mar 20, 2023
Mar 09, 2023
Feb 04, 2022
NVS.NB Final Cash Dividend of gross USD 3.32525 paid on Mar 17, 2022 going ex on Mar 08, 2022
Mar 09, 2022
Mar 17, 2022
Mar 08, 2022
Jan 26, 2021
NVS.NB Final Cash Dividend of gross USD 3.199072 paid on Mar 15, 2021 going ex on Mar 04, 2021
Mar 05, 2021
Mar 15, 2021
Mar 04, 2021
Jan 31, 2020
NVS.NB Final Cash Dividend of gross USD 3.087366 paid on Mar 12, 2020 going ex on Mar 03, 2020
Mar 04, 2020
Mar 12, 2020
Mar 03, 2020
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
tradingkey.logo
tradingkey.logo
日內數據由路孚特(Refinitiv)提供,並受使用條款約束。歷史及當前收盤數據均由路孚特提供。所有報價均以當地交易所時間為準。美股報價的即時最後成交數據僅反映透過納斯達克報告的交易。日內數據延遲至少15分鐘或遵循交易所要求。
* 參考、分析和交易策略由提供商Trading Central提供,觀點基於分析師的獨立評估和判斷,未考慮投資者的投資目標和財務狀況。
風險提示:我們的網站和行動應用程式僅提供關於某些投資產品的一般資訊。Finsights 不提供財務建議或對任何投資產品的推薦,且提供此類資訊不應被解釋為 Finsights 提供財務建議或推薦。
投資產品存在重大投資風險,包括可能損失投資的本金,且可能並不適合所有人。投資產品的過去表現並不代表其未來表現。
Finsights 可能允許第三方廣告商或關聯公司在我們的網站或行動應用程式的任何部分放置或投放廣告,並可能根據您與廣告的互動情況獲得報酬。
© 版權所有: FINSIGHTS MEDIA PTE. LTD. 版權所有